As clinical trials of SHP2 allosteric inhibitors emerge, our finding of SHP2-mediated immunosuppression in colorectal tumorigenesis lays the foundation for combining immune checkpoint inhibitors and the SHP2 inhibitor in CRC immunotherapy. Here, PTPN11 is linked to colorectal carcinoma.